Can-Fite BioPharma Ltd. announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will take place at one of the world's premier scientific meetings in oncology, providing a platform to showcase clinical findings to the global community. Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease, and a patient who received Namodenoson as second-line therapy remains alive more than 18 months.

The Phase 2a study evaluated oral Namodenoson in patients with advanced pancreatic cancer who had progressed following prior standard therapies. The study successfully achieved its primary safety endpoint and demonstrated encouraging survival outcomes together with durable disease stabilization in this difficult-to-treat patient population.

Namodenoson is a highly selective A3 adenosine receptor agonist with a unique mechanism of action that induces apoptosis of cancer cells while exhibiting an excellent safety profile. The drug has demonstrated anti-tumor activity across multiple preclinical models, including pancreatic cancer, and is also being developed for hepatocellular carcinoma and MASH.

Clinical Development Plans

Can-Fite is currently planning the next stage of clinical development for Namodenoson in pancreatic cancer. A Phase 2b study is designed to evaluate Namodenoson in combination with chemotherapy, based on encouraging clinical findings and supportive preclinical evidence demonstrating synergistic anti-tumor activity.

Key Study Details

"We are pleased that our abstract has been selected for presentation at ESMO, one of the most prestigious international oncology conferences," said Pnina Fishman, Ph.D., Chairperson and Chief Scientific Officer of Can-Fite BioPharma. "Acceptance by ESMO provides important scientific recognition of our pancreatic cancer program and offers an opportunity to present our clinical findings to the global oncology community. We believe these data further support the continued development of Namodenoson for patients with advanced pancreatic cancer."

Additional details regarding the poster presentation, including presentation date, session information, and poster number, will be announced when they become available.

Can-Fite BioPharma has completed enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The study has reached the pre-specified interim analysis stage under a protocol agreed with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Results from the interim analysis, which will evaluate efficacy and safety data, are expected during Q4 2026/Q1 2027.

The Phase 3 trial is a randomized, double-blind, placebo-controlled study designed to demonstrate clinical safety and efficacy. Patients are administered 3 mg Piclidenoson tablets or placebo orally twice daily. The co-primary efficacy objectives include the proportion of subjects achieving a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) and the proportion achieving a Static Physician's Global Assessment (sPGA) of 0 or 1 at Week 16.

Piclidenoson is a first-in-class oral A3 adenosine receptor (A3AR) agonist with a differentiated mechanism of action targeting key inflammatory pathways implicated in psoriasis. Unlike injectable biologic therapies, Piclidenoson is administered orally as a tablet. It has demonstrated a favourable safety profile in more than 1,500 subjects treated across clinical studies, supporting its potential use as a chronic long-term treatment.

Study Details